

REMARKS

The amendments to the specification as set forth above are intended to clarify and set apart the various sections of the subject application.

The amendments to the claims as set forth above are intended to remove all multiple dependent claims from the subject application and to more particularly point out and distinctly claim the subject invention.

Attached hereto is a marked-up version of the specification and claims 3 and 6-15, which illustrates all of the changes made to the specification and claims pursuant to 37 CFR §1.121. The attached page is captioned "Version With Markings To Show Changes Made". Deleted language is bracketed and added language is underlined.


The Commissioner is hereby authorized to charge any deficiencies or credit any overpayments in connection with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 3-21-02

By:


Richard E. Jenkins
Reg. No.: 28,428

Suite 1400 University Tower
3100 Tower Boulevard
Durham, North Carolina 27707
Telephone: (919) 493-8000
Facsimile: (919) 419-0383



1406/50

REJ/lsg

Serial No.: Not yet assigned

Version With Markings To Show Changes Made

IN THE SPECIFICATION:

The paragraph heading has been inserted on page 1 of the English translation of the subject application, before the title, as follows:

Description

The paragraph heading has been inserted on page 1 of the English translation of the subject application, before the first full paragraph, as follows:

Technical Field

The paragraph heading has been inserted on page 1 of the English translation of the subject application, before the second full paragraph, as follows:

Background Art

The paragraph heading has been inserted on page 5 of the English translation of the subject application, before the first full paragraph, as follows:

Summary of the Invention

The paragraph heading has been inserted on page 5 of the English translation of the subject application, before the second fully paragraph, as follows:

Brief Description of the Drawings

The paragraph heading has been inserted on page 6 of the English translation of the subject application, before the third full paragraph, as follows:

Detailed Description of the Invention

IN THE CLAIMS:

The paragraph heading "Patent Claims" on page 40 of the English translation of the amended claims according to PCT Rule 66.4 has been deleted and the paragraph heading has been inserted in place thereof as follows:

CLAIMS

The paragraph heading has been inserted on page 40 of the English translation of the amended claims according to PCT Rule 66.4, before claim 1, as follows:

What is claimed is:

3. (Amended) Method according to claim [1 or claim] 2 wherein the eukaryotic cell is a tumor cell or a cell infected by a microorganism.
6. (Amended) Method according to [one or more of claims 1 to 5] claim 1 wherein the negative strand RNAs derived from the cDNA or the DNA of the gene library are introduced into one or more segments of the modified influenza viruses and/or as an additional segment into the modified influenza viruses.
7. (Amended) Method according to claim 1 [or claim 6] wherein the modified influenza viruses are modified influenza A viruses.

8. (Amended) Method according to claim 6 [or claim 7] wherein the preparation of negative strand RNA is performed by transcription of the pseudoviral gene segments with RNA polymerase I.
9. (Amended) Method according to [one or more of claims 1 to 8] claim 1 wherein following step (b), by means of selection a concentration of the recombinant virus particles is performed and/or the recombinant virus particles are isolated.
10. (Amended) Method according to [one or more of claims 1 to 9] claim 1 wherein after introducing the cDNA or the DNA of the gene library a superinfection is carried out using wild type influenza virus.
11. (Amended) Method according to [one or more of claims 1 to 10] claim 1 wherein immortalization of the antigen-presenting cells is carried out using EBV genes or oncogenes.
12. (Amended) Method according to [one or more of claims 1 to 11] claim 1 wherein B cells or dendritic cells are used as the antigen-presenting cells.
13. (Amended) Method according to [one or more of claims 1 to 12] claim 1 wherein the cleavage products of the proteins are presented on the B cell in a complex with MHC class I or MHC class II.
14. (Amended) Method according to [one or more of claims 1 to 13] claim 1 or 13 wherein co-cultivation of the B cells is performed with T helper cells in the case of MHC class II-restricted antigens and with cytotoxic T cells in the case of MHC class I-restricted antigens.
15. (Amended) Method according to [one or more of claims 1 to 14] claim 1 wherein stimulation of the antigen-specific T cells is measured by cytokine release, by T cell proliferation, or by detection of the cytotoxic activity of the T cells.
- [17. Use of modified influenza viruses having an enhanced transcription, replication, and/or expression rate as compared to the wild type for identifying MHC-restricted antigens.]